Skip to main content

Table 2 18F-FDG accumulation in the mainly involved organs and tissues in patients with AOSD compared with healthy controls

From: Total metabolic lesion volume of lymph nodes measured by 18F-FDG PET/CT: a new predictor of macrophage activation syndrome in adult-onset Still’s disease

 

N (%)

SUVmax in patients with AOSD

Bilateral (n)

SUVmax in healthy controls

p

Bone marrow

5.10 (4.25–6.10)

3.76 (3.00–4.15)

< 0.001

Spleen

3.70 (3.05–4.35)

2.28 (2.06–2.56)

< 0.001

Liver

3.20 (2.80–3.60)

3.26 (2.88–3.58)

0.672

Lymph nodes#

38 (66.67)

5.55 (4.05–8.68)

 Cervical LN

30 (52.63)

5.15 (3.92–7.85)

26/30

 Axillary LN

27 (47.37)

4.70 (2.70–6.00)

25/27

 Mediastinum LN

19 (33.33)

5.30 (3.70–8.90)

 Pelvic LN

16 (28.07)

6.45 (4.68–8.52)

 Retroperitoneal LN

14 (24.56)

5.60 (3.15–7.72)

 Inguinal LN

13 (22.81)

4.20 (2.65–5.20)

10/13

 Abdominal LN

8 (14.04)

6.60 (5.25–7.70)

  1. Data are presented in the form of median (Q1–Q3) as continuous variable
  2. SUV standardized uptake value
  3. #This was calculated from the patients with hypermetabolic lymph nodes (n = 38). SUVmax was the maximum SUV of the regional lymph node